Gene info: ID 3932

Gene: LCK

GENE ID: 3932

Synonyms: IMD22|LSK|YT16|p56lck|pp58lck

Description: LCK proto-oncogene, Src family tyrosine kinase

Gene type: protein-coding

Location: 1p35.2

dbXrefs: Ensembl:ENSG00000182866 MIM:153390 Vega:OTTHUMG00000007463 UniprotKB:P06239

RefSeq: NG_023387.1

Retrived from: PubMed

SNPs: 0 ANCO-SNPs

Phenotype: ND

# Publications: 2

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 4.330e-1 (AD) 8.511e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
CD2	0.866
GZMA	0.816
SLAMF7	0.809
TBX21	0.806
CTSW	0.801
IL2RB	0.799
LY9	0.798
EOMES	0.794
NKG7	0.779
CD3G	0.778

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
EFNA5	-0.451
CYP46A1	-0.448
CHST1	-0.443
WIPF3	-0.442
OGDHL	-0.442
GDF10	-0.441
MARCH11	-0.44
HTR5A	-0.44
CA7	-0.438
KIAA0319	-0.437

ID	Drug Name	Drug Type	CAS Num	Status	Role
DB01254	Dasatinib	Small Molecule	302962-49-8	Approved\|Investigational	Target
DB01830	{4-[2-Acetylamino-2-(3-Carbamoyl-2-Cyclohexylmethoxy-6,7,8,9-Tetrahydro-5h-Benzocyclohepten-5ylcarbamoyl)-Ethyl]-2-Phosphono-Phenyl}-Phosphonic Acid	Small Molecule		Experimental	Target
DB02010	Staurosporine	Small Molecule	62996-74-1	Experimental	Target
DB03023	1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine	Small Molecule		Experimental	Target
DB04003	{4-[(2S)-2-Acetamido-3-({(1S)-1-[3-carbamoyl-4-(cyclohexylmethoxy)phenyl]ethyl}amino)-3-oxopropyl]-2-phosphonophenoxy}acetic acid	Small Molecule		Experimental	Target
DB04395	Phosphoaminophosphonic Acid-Adenylate Ester	Small Molecule		Experimental	Target
DB06925	3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE	Small Molecule		Experimental	Target
DB07146	2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE	Small Molecule		Experimental	Target
DB07297	5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE	Small Molecule		Experimental	Target
DB08055	N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine	Small Molecule		Experimental	Target
DB08056	N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine	Small Molecule		Experimental	Target
DB08057	N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine	Small Molecule		Experimental	Target
DB08901	Ponatinib	Small Molecule	943319-70-8	Approved\|Investigational	Target
DB09079	Nintedanib	Small Molecule	656247-17-5	Approved	Target

ID	Drug Name	Action	PubMed
C052383	1,1-bis(4-hydroxyphenyl)-2-phenylbut-1-ene	"1,1-bis(4-hydroxyphenyl)-2-phenylbut-1-ene results in decreased expression of LCK mRNA"	23373633
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LCK mRNA"	27188386
C549569	4-cyano-N-(2-(1-cyclohexen-1-yl)-4-(1-((dimethylamino)acetyl)-4-piperidinyl)phenyl)-1H-imidazole-2-carboxamide	4-cyano-N-(2-(1-cyclohexen-1-yl)-4-(1-((dimethylamino)acetyl)-4-piperidinyl)phenyl)-1H-imidazole-2-carboxamide results in decreased activity of LCK protein	22039836
C027576	4-hydroxy-2-nonenal	4-hydroxy-2-nonenal results in decreased expression of LCK mRNA	12419474
C471843	6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine	6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine results in decreased activity of LCK protein	12534346
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LCK mRNA"	27188386
C054852	7-hydroxystaurosporine	7-hydroxystaurosporine results in decreased activity of LCK protein	10998351
C072876	A 771726	A 771726 inhibits the reaction [TNF protein results in increased activity of LCK protein]	9973483
C014949	acetylhydrazine	acetylhydrazine results in decreased expression of LCK mRNA	15282401
C016601	afimoxifene	afimoxifene results in decreased expression of LCK mRNA	23373633
C412373	AG 1879	AG 1879 inhibits the reaction [bis(2-hydroxy-2-ethylbutanoato)oxochromate(V) results in increased phosphorylation of LCK protein]	14572611
C412373	AG 1879	AG 1879 inhibits the reaction [Potassium Dichromate results in increased phosphorylation of LCK protein]	14572611
D024502	alpha-Tocopherol	alpha-Tocopherol inhibits the reaction [bis(2-hydroxy-2-ethylbutanoato)oxochromate(V) results in increased phosphorylation of LCK protein]	14572611
D024502	alpha-Tocopherol	alpha-Tocopherol inhibits the reaction [Potassium Dichromate results in increased phosphorylation of LCK protein]	14572611
C120793	alsterpaullone	alsterpaullone results in decreased activity of LCK protein	12534346
D018501	Antirheumatic Agents	Antirheumatic Agents results in decreased expression of LCK mRNA	24449571
D017639	Asbestos, Amosite	"Asbestos, Amosite results in increased activity of LCK protein"	29112861
D017638	Asbestos, Crocidolite	"Asbestos, Crocidolite affects the expression of LCK mRNA"	17331233
D001205	Ascorbic Acid	Ascorbic Acid inhibits the reaction [bis(2-hydroxy-2-ethylbutanoato)oxochromate(V) results in increased phosphorylation of LCK protein]	14572611
D001205	Ascorbic Acid	Ascorbic Acid inhibits the reaction [Potassium Dichromate results in increased phosphorylation of LCK protein]	14572611
D001241	Aspirin	Aspirin results in decreased expression of LCK mRNA	15928584
C046196	atractylon	atractylon inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased activity of LCK protein]	27553716
D001280	Atrazine	Atrazine results in decreased expression of LCK mRNA	25929836
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of LCK mRNA	21569818
D004958	Estradiol	Estradiol results in decreased expression of LCK mRNA	23373633
D004958	Estradiol	[Progesterone co-treated with Estradiol] results in decreased expression of LCK mRNA	17404688
D004958	Estradiol	Estradiol results in decreased expression of LCK mRNA	19484750
C483161	beta-hydroxy simvastatin acid	beta-hydroxy simvastatin acid results in decreased expression of LCK mRNA	18192240
C004541	biochanin A	biochanin A inhibits the reaction [CXCL8 protein results in increased phosphorylation of LCK protein]	22387535
C083520	bis(2-hydroxy-2-ethylbutanoato)oxochromate(V)	AG 1879 inhibits the reaction [bis(2-hydroxy-2-ethylbutanoato)oxochromate(V) results in increased phosphorylation of LCK protein]	14572611
C083520	bis(2-hydroxy-2-ethylbutanoato)oxochromate(V)	alpha-Tocopherol inhibits the reaction [bis(2-hydroxy-2-ethylbutanoato)oxochromate(V) results in increased phosphorylation of LCK protein]	14572611
C083520	bis(2-hydroxy-2-ethylbutanoato)oxochromate(V)	Ascorbic Acid inhibits the reaction [bis(2-hydroxy-2-ethylbutanoato)oxochromate(V) results in increased phosphorylation of LCK protein]	14572611
C083520	bis(2-hydroxy-2-ethylbutanoato)oxochromate(V)	bis(2-hydroxy-2-ethylbutanoato)oxochromate(V) results in increased phosphorylation of LCK protein	14572611
C083520	bis(2-hydroxy-2-ethylbutanoato)oxochromate(V)	CAT protein inhibits the reaction [bis(2-hydroxy-2-ethylbutanoato)oxochromate(V) results in increased phosphorylation of LCK protein]	14572611
C083520	bis(2-hydroxy-2-ethylbutanoato)oxochromate(V)	Glutathione inhibits the reaction [bis(2-hydroxy-2-ethylbutanoato)oxochromate(V) results in increased phosphorylation of LCK protein]	14572611
C472777	bisperoxovanadium	LCK protein affects the reaction [bisperoxovanadium results in increased expression of PTGS2 mRNA]	12493747
C006780	bisphenol A	bisphenol A results in decreased methylation of LCK promoter	27312807
C006780	bisphenol A	bisphenol A affects the expression of LCK mRNA	25181051
C006780	bisphenol A	bisphenol A results in increased expression of LCK mRNA	18180321
C471992	bosutinib	bosutinib results in decreased activity of LCK protein	17114238
D002737	Chloroprene	Chloroprene results in decreased expression of LCK mRNA	23125180
C074702	chromium hexavalent ion	chromium hexavalent ion results in increased activity of LCK protein	12902192
C074702	chromium hexavalent ion	LCK protein affects the reaction [chromium hexavalent ion results in increased expression of IL6 mRNA]	17078813
C074702	chromium hexavalent ion	LCK protein affects the reaction [chromium hexavalent ion results in increased phosphorylation of STAT3 protein alternative form]	17078813
D003300	Copper	Copper deficiency results in increased expression of LCK mRNA	26033743
C551994	crizotinib	crizotinib results in decreased activity of LCK protein	21812414
D003471	Cuprizone	Cuprizone results in increased expression of LCK mRNA	27523638
D003513	Cycloheximide	Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of LCK mRNA]	11007951
D003520	Cyclophosphamide	Cyclophosphamide results in decreased expression of LCK mRNA	21041162
C079170	damnacanthal	damnacanthal inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased activity of LCK protein]	27553716
D000069439	Dasatinib	Dasatinib results in decreased activity of LCK protein	18550857
D003907	Dexamethasone	Dexamethasone results in decreased expression of LCK mRNA	21041162
D004041	Dietary Fats	Dietary Fats results in increased expression of LCK mRNA	23409006
D019422	Dietary Sucrose	Dietary Sucrose results in increased expression of LCK mRNA	26033743
D004054	Diethylstilbestrol	Diethylstilbestrol results in decreased expression of LCK mRNA	21041162
D015127	9,10-Dimethyl-1,2-benzanthracene	"9,10-Dimethyl-1,2-benzanthracene results in increased expression of LCK mRNA"	19480007
D004365	Drugs, Chinese Herbal	"Drugs, Chinese Herbal results in decreased activity of LCK protein"	25856345
C118739	entinostat	entinostat results in increased expression of LCK mRNA	26272509
C118739	entinostat	"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LCK mRNA"	27188386
D004997	Ethinyl Estradiol	Ethinyl Estradiol affects the expression of LCK mRNA	17555576
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in increased expression of LCK mRNA	17942748
C546771	gardiquimod	gardiquimod results in decreased expression of LCK mRNA	28003376
C546771	gardiquimod	Protein Kinase Inhibitors inhibits the reaction [gardiquimod results in decreased expression of LCK mRNA]	28003376
D005839	Gentamicins	Gentamicins results in increased expression of LCK mRNA	22061828
D005978	Glutathione	Glutathione inhibits the reaction [bis(2-hydroxy-2-ethylbutanoato)oxochromate(V) results in increased phosphorylation of LCK protein]	14572611
D005978	Glutathione	Glutathione inhibits the reaction [Potassium Dichromate results in increased phosphorylation of LCK protein]	14572611
C029424	hydrazine	hydrazine results in decreased expression of LCK mRNA	15282401
D000068877	Imatinib Mesylate	Imatinib Mesylate results in decreased phosphorylation of LCK protein	15100154
C474021	indirubin-3'-monoxime	indirubin-3'-monoxime results in decreased activity of LCK protein	12534346
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in decreased expression of LCK mRNA	22802445\|2675264
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in increased expression of LCK mRNA	24332044
C119620	kenpaullone	kenpaullone results in decreased activity of LCK protein	12534346
D007657	Ketone Bodies	Ketone Bodies results in decreased expression of LCK mRNA	16807920
C008261	lead acetate	lead acetate results in increased expression of LCK mRNA	21829687
D008043	Linseed Oil	Linseed Oil results in increased expression of LCK mRNA	23409006
D058185	Magnetite Nanoparticles	[Succimer binds to Magnetite Nanoparticles] which results in increased expression of LCK mRNA	21641980
D058185	Magnetite Nanoparticles	[Succimer co-treated with Magnetite Nanoparticles] results in increased expression of LCK mRNA	26378955
C025340	manganese chloride	[manganese chloride co-treated with LCK protein] results in increased phosphorylation of CD28 protein	8662792
C025340	manganese chloride	Tetradecanoylphorbol Acetate inhibits the reaction [[manganese chloride co-treated with LCK protein] results in increased phosphorylation of CD28 protein]	8662792
D008727	Methotrexate	LCK protein affects the susceptibility to Methotrexate	16217747
C013598	methoxyacetic acid	methoxyacetic acid affects the expression of LCK mRNA	20864626
D003189	p-Methoxy-N-methylphenethylamine	atractylon inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased activity of LCK protein]	27553716
D003189	p-Methoxy-N-methylphenethylamine	damnacanthal inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased activity of LCK protein]	27553716
D003189	p-Methoxy-N-methylphenethylamine	p-Methoxy-N-methylphenethylamine results in increased activity of LCK protein	27553716
D003189	p-Methoxy-N-methylphenethylamine	pyeongwee-san extract inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased activity of LCK protein]	27553716
C004925	methylmercuric chloride	methylmercuric chloride results in increased expression of LCK mRNA	28001369
D015655	1-Methyl-4-phenylpyridinium	1-Methyl-4-phenylpyridinium results in increased expression of LCK mRNA	22776087
D037742	Nanotubes, Carbon	"Nanotubes, Carbon analog results in decreased expression of LCK mRNA"	25554681
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in decreased expression of LCK mRNA"	25554681
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in increased activity of LCK protein"	29112861
D009532	Nickel	Nickel results in increased expression of LCK mRNA	25583101
D009538	Nicotine	LCK protein promotes the reaction [Nicotine results in increased phosphorylation of and results in increased activity of FYN protein]	17709503
D009538	Nicotine	Nicotine results in increased phosphorylation of and results in increased activity of LCK protein	17709503
C507134	ON 01910	ON 01910 results in increased phosphorylation of LCK protein	25472472
C030110	oxaliplatin	[oxaliplatin co-treated with Topotecan] results in increased expression of LCK mRNA	25729387
C006253	pirinixic acid	pirinixic acid results in decreased expression of LCK mRNA	17426115\|2081375
C545373	ponatinib	ponatinib results in decreased activity of LCK protein	19878872
D011192	Potassium Dichromate	AG 1879 inhibits the reaction [Potassium Dichromate results in increased phosphorylation of LCK protein]	14572611
D011192	Potassium Dichromate	alpha-Tocopherol inhibits the reaction [Potassium Dichromate results in increased phosphorylation of LCK protein]	14572611
D011192	Potassium Dichromate	Ascorbic Acid inhibits the reaction [Potassium Dichromate results in increased phosphorylation of LCK protein]	14572611
D011192	Potassium Dichromate	CAT protein inhibits the reaction [Potassium Dichromate results in increased phosphorylation of LCK protein]	14572611
D011192	Potassium Dichromate	Glutathione inhibits the reaction [Potassium Dichromate results in increased phosphorylation of LCK protein]	14572611
D011192	Potassium Dichromate	LCK protein affects the reaction [Potassium Dichromate results in increased expression of IL6 mRNA]	17078813
D011192	Potassium Dichromate	LCK protein affects the reaction [Potassium Dichromate results in increased phosphorylation of STAT3 protein alternative form]	17078813
D011192	Potassium Dichromate	Potassium Dichromate results in increased phosphorylation of LCK protein	14572611
D011374	Progesterone	[Progesterone co-treated with Estradiol] results in decreased expression of LCK mRNA	17404688
C005556	propionaldehyde	propionaldehyde results in decreased expression of LCK mRNA	26079696
D011441	Propylthiouracil	Propylthiouracil results in increased expression of LCK mRNA	24780913
D047428	Protein Kinase Inhibitors	Protein Kinase Inhibitors inhibits the reaction [gardiquimod results in decreased expression of LCK mRNA]	28003376
C562348	pyeongwee-san extract	pyeongwee-san extract inhibits the reaction [p-Methoxy-N-methylphenethylamine results in increased activity of LCK protein]	27553716
D011720	Pyrazoles	Pyrazoles analog results in decreased activity of LCK protein	12534346
D011743	Pyrimidines	Pyrimidines analog results in decreased activity of LCK protein	12534346
D015474	Isotretinoin	Isotretinoin results in increased expression of LCK mRNA	20436886
C513635	S-2-pentyl-4-pentynoic hydroxamic acid	S-2-pentyl-4-pentynoic hydroxamic acid results in decreased expression of LCK mRNA	21427059
C093642	SB 203580	SB 203580 results in decreased activity of LCK protein	10998351
D064586	Selenic Acid	Selenic Acid results in increased expression of LCK mRNA	16444006
C017947	sodium arsenite	sodium arsenite results in increased phosphorylation of LCK protein	18407307
C471405	sorafenib	sorafenib results in decreased phosphorylation of LCK protein	21293487
C416927	SU 6656	SU 6656 results in decreased activity of LCK protein	12534346
D004113	Succimer	[Succimer binds to Magnetite Nanoparticles] which results in increased expression of LCK mRNA	21641980
D004113	Succimer	[Succimer co-treated with Magnetite Nanoparticles] results in increased expression of LCK mRNA	26378955
C061133	tamibarotene	tamibarotene results in increased expression of LCK mRNA	15498508
D013629	Tamoxifen	Tamoxifen affects the expression of LCK mRNA	17555576
D013749	Tetrachlorodibenzodioxin	Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of LCK mRNA]	11007951
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of LCK mRNA	11007951\|2791314
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of LCK mRNA	17942748
D013755	Tetradecanoylphorbol Acetate	Tetradecanoylphorbol Acetate inhibits the reaction [[manganese chloride co-treated with LCK protein] results in increased phosphorylation of CD28 protein]	8662792
D008063	Thioctic Acid	Thioctic Acid results in increased phosphorylation of LCK protein	20927401
C009495	titanium dioxide	titanium dioxide results in decreased expression of LCK mRNA	27760801
C009495	titanium dioxide	titanium dioxide results in increased expression of LCK mRNA	23557971
D019772	Topotecan	[oxaliplatin co-treated with Topotecan] results in increased expression of LCK mRNA	25729387
D014212	Tretinoin	Tretinoin results in increased expression of LCK mRNA	15498508
D014212	Tretinoin	Tretinoin results in decreased expression of LCK mRNA	20488242
D014241	Trichloroethylene	Trichloroethylene results in increased phosphorylation of LCK protein	22467029
C012589	trichostatin A	trichostatin A results in increased expression of LCK mRNA	24935251
C013320	tris(2-butoxyethyl) phosphate	tris(2-butoxyethyl) phosphate affects the expression of LCK mRNA	29024780
D014635	Valproic Acid	Valproic Acid affects the expression of LCK mRNA	25979313
D014635	Valproic Acid	Valproic Acid results in increased expression of LCK mRNA	24383497\|2800136
D014635	Valproic Acid	Valproic Acid results in increased methylation of LCK gene	29154799
D014635	Valproic Acid	Valproic Acid results in decreased expression of LCK mRNA	21427059
D015032	Zinc	Zinc deficiency results in increased expression of LCK mRNA	11739864
D015032	Zinc	Zinc deficiency results in increased expression of LCK protein	11739864
D019287	Zinc Sulfate	Zinc Sulfate results in increased expression of LCK mRNA	27504894

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0001784	phosphotyrosine residue binding	-	IPI	20624904
GO:0004713	protein tyrosine kinase activity	-	EXP	1381360 9799234 12923167 18697750
GO:0004713	protein tyrosine kinase activity	-	IDA	214242
GO:0004713	protein tyrosine kinase activity	-	IMP	8681956
GO:0004713	protein tyrosine kinase activity	-	ISS	-
GO:0004713	protein tyrosine kinase activity	-	TAS	-
GO:0004715	non-membrane spanning protein tyrosine kinase activity	-	IBA	21873635
GO:0004722	protein serine/threonine phosphatase activity	-	IDA	8506364
GO:0004722	protein serine/threonine phosphatase activity	-	ISS	-
GO:0005102	signaling receptor binding	-	IBA	21873635
GO:0005515	protein binding	-	IPI	7507203 7513706 7721825 7852312 8114715 8246987 8551220 8576115 8621719 8626561 8650207 8798676 9045636 9175835 9341123 10209036 10318843 10369126 10553045 10556826 10656681 11278465 11741929 14625311 14757743 15536084 15554700 15743820 15827961 16051843 16099425 16107303 16195219 16245368 16461343 16839418 16888650 16899217 16938345 17005671 17382937 18424730 18539162 19167335 19192391 20100835 21719704 21725281 21964608 22939624 23460737 24728074 25241761 25416956 26871637 27335501
GO:0005524	ATP binding	-	IEA	-
GO:0008022	protein C-terminus binding	-	IPI	16245368
GO:0016301	kinase activity	-	TAS	-
GO:0019901	protein kinase binding	-	IPI	8618896
GO:0019903	protein phosphatase binding	-	IPI	22080863
GO:0042169	SH2 domain binding	-	IPI	7852312 8794306
GO:0042169	SH2 domain binding	-	ISS	-
GO:0042608	T cell receptor binding	-	IPI	8681956
GO:0042609	CD4 receptor binding	-	IPI	7486703
GO:0042610	CD8 receptor binding	-	IPI	2470098
GO:0042802	identical protein binding	-	IPI	17118402 24463463
GO:0043548	phosphatidylinositol 3-kinase binding	-	IPI	7504174
GO:0046934	phosphatidylinositol-4,5-bisphosphate 3-kinase activity	-	TAS	-
GO:0051117	ATPase binding	-	IPI	15671290

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0006468	protein phosphorylation	-	IDA	214242
GO:0006470	protein dephosphorylation	-	IEA	-
GO:0006882	cellular zinc ion homeostasis	-	IEP	11739864
GO:0006882	cellular zinc ion homeostasis	-	ISS	-
GO:0006919	activation of cysteine-type endopeptidase activity involved in apoptotic process	-	IDA	16116473
GO:0006919	activation of cysteine-type endopeptidase activity involved in apoptotic process	-	ISS	-
GO:0007169	transmembrane receptor protein tyrosine kinase signaling pathway	-	IBA	21873635
GO:0018108	peptidyl-tyrosine phosphorylation	-	IMP	8681956
GO:0030097	hemopoiesis	-	NAS	12884910
GO:0030154	cell differentiation	-	IBA	21873635
GO:0030168	platelet activation	-	TAS	-
GO:0030217	T cell differentiation	-	IBA	21873635
GO:0030217	T cell differentiation	-	IMP	1579166
GO:0030217	T cell differentiation	-	ISS	-
GO:0031295	T cell costimulation	-	TAS	-
GO:0038083	peptidyl-tyrosine autophosphorylation	-	IBA	21873635
GO:0042127	regulation of cell proliferation	-	IBA	21873635
GO:0042493	response to drug	-	IDA	16116473
GO:0042493	response to drug	-	ISS	-
GO:0042981	regulation of apoptotic process	-	IBA	21873635
GO:0045087	innate immune response	-	IBA	21873635
GO:0046854	phosphatidylinositol phosphorylation	-	IEA	-
GO:0050690	regulation of defense response to virus by virus	-	TAS	-
GO:0050852	T cell receptor signaling pathway	-	TAS	-
GO:0050853	B cell receptor signaling pathway	-	IBA	21873635
GO:0050862	positive regulation of T cell receptor signaling pathway	-	NAS	12614355
GO:0050870	positive regulation of T cell activation	-	IDA	8943371
GO:0050870	positive regulation of T cell activation	-	ISS	-
GO:0050900	leukocyte migration	-	TAS	-
GO:0051209	release of sequestered calcium ion into cytosol	-	ISS	-
GO:0051249	regulation of lymphocyte activation	-	NAS	7852312
GO:0051897	positive regulation of protein kinase B signaling	-	TAS	-
GO:2001244	positive regulation of intrinsic apoptotic signaling pathway	-	IMP	16116473
GO:2001244	positive regulation of intrinsic apoptotic signaling pathway	-	ISS	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0000242	pericentriolar material	-	IDA	7513706
GO:0000242	pericentriolar material	-	ISS	-
GO:0001772	immunological synapse	-	IDA	20007709
GO:0005829	cytosol	-	TAS	-
GO:0005886	plasma membrane	-	IDA	12150984
GO:0005886	plasma membrane	-	TAS	-
GO:0031234	extrinsic component of cytoplasmic side of plasma membrane	-	IBA	21873635
GO:0045121	membrane raft	-	IDA	12150984 12732664
GO:0045121	membrane raft	-	ISS	-
GO:0070062	extracellular exosome	-	HDA	20458337

KEGG ID	KEGG Term
hsa04380	Osteoclast differentiation
hsa04650	Natural killer cell mediated cytotoxicity
hsa04660	T cell receptor signaling pathway
hsa05340	Primary immunodeficiency

Reactome ID	Reactome Term	Evidence
R-HSA-109582	Hemostasis	TAS
R-HSA-114604	GPVI-mediated activation cascade	TAS
R-HSA-1257604	PIP3 activates AKT signaling	TAS
R-HSA-1280215	Cytokine Signaling in Immune system	TAS
R-HSA-1280218	Adaptive Immune System	TAS
R-HSA-1433557	Signaling by SCF-KIT	TAS
R-HSA-1433557	Signaling by SCF-KIT	IEA
R-HSA-1433559	Regulation of KIT signaling	TAS
R-HSA-162582	Signal Transduction	TAS
R-HSA-162582	Signal Transduction	IEA
R-HSA-162906	HIV Infection	TAS
R-HSA-162909	Host Interactions of HIV factors	TAS
R-HSA-1643685	Disease	TAS
R-HSA-164938	Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters	TAS
R-HSA-164944	Nef and signal transduction	TAS
R-HSA-164952	The role of Nef in HIV-1 replication and disease pathogenesis	TAS
R-HSA-167590	Nef Mediated CD4 Down-regulation	TAS
R-HSA-168249	Innate Immune System	TAS
R-HSA-168249	Innate Immune System	IEA
R-HSA-168256	Immune System	TAS
R-HSA-168256	Immune System	IEA
R-HSA-199418	Negative regulation of the PI3K/AKT network	TAS
R-HSA-202403	TCR signaling	TAS
R-HSA-202424	Downstream TCR signaling	TAS
R-HSA-202427	Phosphorylation of CD3 and TCR zeta chains	TAS
R-HSA-202430	Translocation of ZAP-70 to Immunological synapse	TAS
R-HSA-202433	Generation of second messenger molecules	TAS
R-HSA-202733	Cell surface interactions at the vascular wall	TAS
R-HSA-210990	PECAM1 interactions	TAS
R-HSA-2172127	DAP12 interactions	TAS
R-HSA-2172127	DAP12 interactions	IEA
R-HSA-2219528	PI3K/AKT Signaling in Cancer	TAS
R-HSA-2219530	Constitutive Signaling by Aberrant PI3K in Cancer	TAS
R-HSA-2424491	DAP12 signaling	TAS
R-HSA-2424491	DAP12 signaling	IEA
R-HSA-388841	Costimulation by the CD28 family	TAS
R-HSA-389356	CD28 co-stimulation	TAS
R-HSA-389357	CD28 dependent PI3K/Akt signaling	TAS
R-HSA-389359	CD28 dependent Vav1 pathway	TAS
R-HSA-389513	CTLA4 inhibitory signaling	TAS
R-HSA-389948	PD-1 signaling	TAS
R-HSA-449147	Signaling by Interleukins	TAS
R-HSA-451927	Interleukin-2 family signaling	TAS
R-HSA-5663202	Diseases of signal transduction	TAS
R-HSA-5663205	Infectious disease	TAS
R-HSA-6811558	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	TAS
R-HSA-76002	Platelet activation, signaling and aggregation	TAS
R-HSA-9006925	Intracellular signaling by second messengers	TAS
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	TAS
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	IEA
R-HSA-9020558	Interleukin-2 signaling	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
27157991	Severe Reduction in Number and Function of Peripheral T Cells Does Not Afford Protection toward Emphysema and Bronchial Remodeling Induced in Mice by Cigarette Smoke. (2016 Jul)	De Cunto G	Am J Pathol
21930963	Prenatal secondhand cigarette smoke promotes Th2 polarization and impairs goblet cell differentiation and airway mucus formation. (2011 Nov 1)	Singh SP	J Immunol